HS 10241Alternative Names: HS-10241
Latest Information Update: 03 Dec 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Proto oncogene protein c met inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Nov 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in China (PO) (NCT02977364)
- 01 Sep 2016 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Monotherapy) in Australia (PO) (NCT02759640)
- 29 Apr 2016 Preclinical trials in Solid tumours in China (PO) before April 2016